Medifast director Chard's trust sells 9,545 shares

Both trust sales were reported under a Rule 10b5-1 plan; Chard also reported direct shares and shares held in a joint account.

Rhea-AI Filing Summary

Medifast director Daniel R. Chard reported sales by The Dan and Allyson Family Irrevocable Trust of 9,545 common shares on September 28, 2026, at a weighted-average price of $11.9788 per share; transaction prices ranged from $11.900 to $12.125, inclusive. The trust sold 9,544 shares on September 29 at a weighted-average price of $11.7300 per share, with transaction prices from $11.670 to $11.810, inclusive. Chard is the trust’s settlor and investment trustee, and the sales were reported under a Rule 10b5-1 plan.

Insider Trade Summary 10b5-1

Net Seller: 19,089 shares

Net Sell 4 txns

Insider Chard Daniel R

Role Director

Sold 19,089 shs ($226K)

Type	Security	Shares	Price	Value
Sale	Common Stock F3, F2	9,544	$11.73	$112K
Sale	Common Stock F1, F2	9,545	$11.9788	$114K
holding	Common Stock F4	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 130,609.352 shares (Indirect, The Dan and Allyson Family Irrevocable Trust); Common Stock — 17,678 shares (Indirect, Dan and Allyson as Joint Tenants); Common Stock — 188,233 shares (Direct)

Footnotes (4)

1. F1. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $11.900 to $12.125, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
2. F2. These shares are directly owned by The Dan and Allyson Family Irrevocable Trust, for which the reporting person is the Settlor of the Trust and Investment Trustee.
3. F3. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $11.670 to $11.810, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
4. F4. These shares are directly owned by a joint account of which the reporting person owns as a joint tenant with his spouse.

Key Figures

Common shares sold: 9,545 shares Weighted-average sale price: $11.9788 per share Common shares sold: 9,544 shares +3 more

6 metrics

Common shares sold 9,545 shares September 28, 2026

Weighted-average sale price $11.9788 per share September 28, 2026; transaction prices ranged from $11.900 to $12.125, inclusive

Common shares sold 9,544 shares September 29, 2026

Weighted-average sale price $11.7300 per share September 29, 2026; transaction prices ranged from $11.670 to $11.810, inclusive

Direct common shares reported 188,233 shares September 28, 2026

Joint-account common shares reported 17,678 shares September 28, 2026; held jointly with Chard’s spouse

Key Terms

weighted-average price, Rule 10b5-1 plan, Settlor, Investment Trustee

4 terms

weighted-average price financial

"The price reported in Column 4 is a weighted-average price."

Weighted-average price is the average of multiple prices where each price is counted according to its size or importance—larger trades carry more weight than smaller ones, like averaging course grades by credit hours. It matters to investors because it gives a more realistic picture of the true price paid or received, helping assess trade execution, compare performance, calculate cost basis, and value positions more accurately than a simple average.

Rule 10b5-1 plan regulatory

"The sales were reported under a Rule 10b5-1 plan."

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

Settlor technical

"the reporting person is the Settlor of the Trust"

Investment Trustee technical

"Settlor of the Trust and Investment Trustee"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many MED shares did the trust sell, and at what prices?

The Dan and Allyson Family Irrevocable Trust sold 9,545 shares on September 28, 2026, at a weighted-average $11.9788 per share, and 9,544 shares on September 29 at a weighted-average $11.7300 per share. Both sales were reported under a Rule 10b5-1 plan.

What MED shares did Daniel R. Chard report holding?

As of September 28, 2026, Daniel R. Chard reported 188,233 directly held common shares and 17,678 common shares in a joint account held with his spouse as joint tenants.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/30/2026 - 08:05 PM Accepted by SEC EDGAR 09/30/2026 - 08:04 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Chard Daniel R

(Last) (First) (Middle)

C/O MEDIFAST, INC.

1501 S. CLINTON STREET, SUITE 500

(Street)

BALTIMORE MARYLAND 21224

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MEDIFAST INC [ MED ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/28/2026		S		9,545	D	$11.9788(1)	140,153.352	I	The Dan and Allyson Family Irrevocable Trust(2)
Common Stock	09/29/2026		S		9,544	D	$11.73(3)	130,609.352	I	The Dan and Allyson Family Irrevocable Trust(2)
Common Stock								17,678	I	Dan and Allyson as Joint Tenants(4)
Common Stock								188,233	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $11.900 to $12.125, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

2. These shares are directly owned by The Dan and Allyson Family Irrevocable Trust, for which the reporting person is the Settlor of the Trust and Investment Trustee.

3. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $11.670 to $11.810, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

4. These shares are directly owned by a joint account of which the reporting person owns as a joint tenant with his spouse.

Remarks:

	/s/ James P. Maloney, attorney-in-fact	09/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)